Treating HCV in people with hemophilia prevents the development of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) and greatly increases the quality of life for people living with hemophilia. There are many obstacles in reaching the WHO goal of globally eradicating HCV by 2030, mainly its scale, complexity, and implementation. That is why many countries have implemented a micro-elimination strategy: a pragmatic elimination approach in populations with the most efficacy. The aim of this publication is to present the morbidity and mortality rates, the clinical course and treatment outcomes of chronic HCV infection in people with hemophilia (PwH), as well as to show an example of a successfully conducted HCV micro-elimination strategy among people with hemophilia in the Province of Vojvodina.

中文翻译：

---

塞尔维亚北部地区血友病患者慢性丙型肝炎感染根除中实施微量消除策略：根除可能吗？

治疗血友病患者的 HCV 可防止终末期肝病 (ESLD) 和肝细胞癌 (HCC) 的发展，并大大提高血友病患者的生活质量。实现世卫组织到 2030 年全球根除 HCV 的目标存在许多障碍，主要是其规模、复杂性和实施。这就是为什么许多国家实施了微量消除策略：在最有效的人群中采取务实的消除方法。本出版物的目的是介绍血友病患者 (PwH) 慢性 HCV 感染的发病率和死亡率、临床过程和治疗结果，并展示在人群中成功实施 HCV 微量消除策略的示例在伏伊伏丁那省患有血友病。